Shield Therapeutics plc (STX) — Cash Flow-to-Debt Ratio
Shield Therapeutics plc (STX) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2025, meaning its operating cash flow of GBX-4.49 Million could theoretically repay 0% of its total liabilities (GBX76.96 Million) in one year. See STX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Shield Therapeutics plc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Shield Therapeutics plc across 11 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Shield Therapeutics plc.
Annual Cash Flow-to-Debt Ratio for Shield Therapeutics plc (2014–2024)
Year-by-year debt coverage analysis for Shield Therapeutics plc. Check Shield Therapeutics plc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.15x | GBX-7.01 Million | GBX46.95 Million | ▲ +89.4% |
| 2023 | -1.40x | GBX-37.13 Million | GBX26.49 Million | ▼ -27.9% |
| 2022 | -1.10x | GBX-18.25 Million | GBX16.65 Million | ▲ +77.9% |
| 2021 | -4.95x | GBX-16.74 Million | GBX3.38 Million | ▼ -696.6% |
| 2020 | -0.62x | GBX-1.40 Million | GBX2.25 Million | ▲ +36.2% |
| 2019 | -0.97x | GBX-4.07 Million | GBX4.17 Million | ▼ -1515.0% |
| 2018 | -0.06x | GBX-178.00K | GBX2.95 Million | ▲ +98.6% |
| 2017 | -4.29x | GBX-16.15 Million | GBX3.76 Million | ▼ -66.9% |
| 2016 | -2.57x | GBX-10.26 Million | GBX3.99 Million | ▼ -1222.0% |
| 2015 | -0.19x | GBX-4.18 Million | GBX21.50 Million | ▼ -12.3% |
| 2014 | -0.17x | GBX-3.34 Million | GBX19.29 Million | — |